title: The Importance of Subgroup Analysis in Drug-Eluting Stent Trials.
authors.affiliation: Division of Cardiology, Brown Medical School, Rhode Island Hospital, Providence, Rhode Island. Electronic address: jabbott@lifespan.org.
authors.forename: J Dawn
authors.initials: JD
authors.lastname: Abbott
mesh_terms: D003324:Coronary Artery Disease / Q000188:drug therapy; D023903:Coronary Restenosis / Q000188:drug therapy*; D054855:Drug-Eluting Stents; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy; D017239:Paclitaxel; D020123:Sirolimus / Q000627:therapeutic use; D015607:Stents; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D017239:Paclitaxel; D020123:Sirolimus
keywords: chronic kidney disease; drug-eluting stent(s); women